Drug Trial Radar · NCT04343651
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Apr 1, 2020
Primary completion
Jul 21, 2020
Study completion Sep 20, 2021
Sponsor
- Lead sponsor
- CytoDyn, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.
Conditions
- Coronavirus Disease 2019
Interventions
PlaceboDrug
Placebo
Leronlimab (700mg)Drug
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Total Symptom ScoreTime frame: Clinical Improvement will be assessed at baseline and at EOT (day 14).
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Palmtree Clinical Research, Inc.
Palm Springs, California
Eisenhower Health
Rancho Mirage, California
Yale
New Haven, Connecticut
Center for Advanced Research & Education (CARE)
Gainesville, Georgia
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Atlantic Health System Hospital
Morristown, New Jersey
Montefiore Medical Center
The Bronx, New York
White Plains Hospital
White Plains, New York
Novant Health
Charlotte, North Carolina
Ohio Health
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.